Aurinia Pharmaceuticals (AUPH) stock slips as RBC Capital Markets downgrades the company following its better than expected ...

Q3 2025 Earnings Call Transcript November 4, 2025 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

Fintel reports that on November 5, 2025, RBC Capital downgraded their outlook for Aurinia Pharmaceuticals (NasdaqGM:AUPH) ...

Aurinia Pharmaceuticals (AUPH) has swung into profitability over the past year, with earnings climbing at an impressive 43.8% per year on average for the past five years. Investors have watched as ...

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.

Aurinia (AUPH) delivered earnings and revenue surprises of +43.75% and +7.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Aurinia alleges that Tidmarsh’s statements were not only inaccurate but also motivated by a personal vendetta against Kevin ...

Reports suggest that, internally, the Food and Drug Administration is facing a crisis of confidence.

Hilliard, the HHS spokesperson, told SFGATE on Tuesday that, “Secretary [Robert F.] Kennedy [Jr.] expects the highest ethical ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.